Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: The EnligHTN I trial by Worthley, S. et al.
 PUBLISHED VERSION  
 
 
Worthley, Stephen Grant; Tsioufis, Costas P.; Worthley, Matthew Ian; Sinhal, Ajay; Chew, Derek P.; 
Meredith, Ian Thomas; Malaiapan, Yuvaraj; Papademetriou, Vasilios  
Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant 
hypertension: The EnligHTN I trial, European Heart Journal, 2013; 34(28):2132-2140. 
 
© The Author 2013. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 























Authors of open access articles are entitled to deposit the final published version of their 
article in institutional and/or centrally organized repositories and can make this publicly 
available immediately upon publication, provided that the journal and OUP are attributed as 
the original place of publication and that correct citation details are given. Authors should also 




25th September 2013 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Safety and efficacy of amulti-electrode renal
sympathetic denervation system in resistant
hypertension: the EnligHTN I trial
Stephen G.Worthley1*, Costas P. Tsioufis2, Matthew I. Worthley1, Ajay Sinhal3,
Derek P. Chew3, Ian T. Meredith4, Yuvi Malaiapan4, and Vasilios Papademetriou2,5
1Cardiovascular Research Centre, c/o The Cardiovascular Investigational Unit, Level 6 Theatre Block, University of Adelaide, Royal Adelaide Hospital, Adelaide 5000, Australia;
2The First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece; 3The Department of Cardiology, Flinders University, Bedford Park, Australia; 4The Monash
Heart and Monash University, Melbourne, Australia; and 5VA and Georgetown University Medical Centers, Washington, DC, USA
Received 26 February 2013; revised 15 May 2013; accepted 16 May 2013; online publish-ahead-of-print 19 June 2013
Aims Catheter-based renal artery sympathetic denervation has emerged as a novel therapy for treatment of patients with drug-
resistant hypertension. Initial studieswere performed using a single electrode radiofrequency catheter, but recent advances
in catheter design have allowed the development ofmulti-electrode systems that can deliver lesionswith a pre-determined





We conducted the first-in-human, prospective, multi-centre, non-randomized study in 46 patients (67%male, mean age
60 years, andmean baseline office blood pressure 176/96 mmHg)with drug-resistant hypertension. The primary efficacy
objectivewas change inofficebloodpressure frombaseline to6months. Safetymeasures included all adverseeventswith
a focus on the renal artery andother vascular complications and changes in renal function. Renal artery denervation, using
the EnligHTN
TM
system significantly reduced the office blood pressure from baseline to 1, 3, and 6 months by 228/10,
227/10 and226/10 mmHg, respectively (P, 0.0001). No acute renal artery injury or other serious vascular complica-
tions occurred. Small, non-clinically relevant, changes in average estimated glomerular filtration ratewere reported from
baseline (87+ 19 mL/min/1.73 m2) to 6 months post-procedure (82+20 mL/min/1.73 m2).
Conclusion Renal sympathetic denervation, using the EnligHTN
TM
multi-electrode catheter results in a rapid and significant office
blood pressure reduction that was sustained through 6 months. The EnligHTN
TM
system delivers a promising therapy
for the treatment of drug-resistant hypertension.
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Introduction
Hypertension (HTN) remains the leading treatable cardiovascular
risk factor throughout the world.1–3 Approximately 1 billion
people worldwide have HTN, and it is projected that this will
increase to 1.5 billion by 2025.4 Treatment of HTN in the USA
consumes .$55 billion healthcare dollars a year and HTN-related
costs account for 10% of the world’s total healthcare expendi-
tures.5,6 Despite availability of multiple pharmacological agents
from different classes to treat HTN, most patients (.50%) do not
achieve goal blood pressure (BP).7,8 In fact one out of every eight
patients with HTN will not achieve appropriate BP targets despite
the use of three or more agents.9 Resistant HTN has a more than
three-fold increase in cardiovascular risk when compared with
treated and controlled patients with HTN.10 Thus, there remains
an unmet clinical need in improving BP control beyond current
pharmacological management strategies.11–13
The renal sympathetic nervous system is thought to be important
in the onset and maintenance of HTN.13,14 Disruption of the renal
sympathetic fibresusing catheter-based radiofrequency (RF) ablation
has been shown to be safe and efficacious in patients with resistant
HTN.15–17 However, the single electrode RF catheter system that
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has been widely used for this technique has the disadvantage of re-
quiring the operator to manipulate the catheter within the renal
artery lumen multiple times to achieve a series of lesions.18 A multi-
electrode RF system, with electrodes geometrically arranged in pre-
specified positions, reduces the amount of catheter manipulation
required within the renal artery and thus potentially reduces the
risk of procedure-related renal artery injury.
The aim of this first-in-human, prospective, multi-centre, non-
randomized study was to evaluate the safety and efficacy of a multi-
electrode RF ablation catheter to interrupt the renal sympathetic
nerve fibres in patients with resistant HTN.
Methods
Study population
Adult patients (18–80 years of age), who had been referred for manage-
ment of resistant HTN by a primary healthcare practitioner or specialist
at four participating centres (three in Australia and one in Greece), were
screened for participation. Enrolled patients had an office systolic BP that
remained ≥160 mmHg (≥150 mmHg for patients with DM) despite the
stable use of ≥ three anti-hypertensive medications concurrently at
maximally tolerated doses. At least one of the anti-hypertensivemedica-
tions was required to be a diuretic. In all participating patients, the anti-
hypertensive drug regimen was to remain stable for a minimum of 14
days prior to enrolment and through the 6-month follow-up.
Patients were withdrawn from the study and the ablation procedure
not performed if the renal artery anatomy met any of the exclusion cri-
teria based on the renal angiogram performed on the day of the sched-
uled ablation procedure. A complete listing of the key eligibility criteria




I study is a first-in-human, prospective, multi-centre,
non-randomized study toevaluate safety andefficacyof amulti-electrode
system for renal artery sympathetic denervation in patients with
drug-resistant hypertensive. The primary safety objective was all
adverse events (AEs) during the study. The primary efficacy objective
was the reduction of office BP compared with baseline at 6 months.
Study patients will continue follow-up at 12, 18, and 24 months post-
denervation procedure. The study was designed with an enrolment
target of 60 patients to achieve a minimum of 30 subjects eligible for
the renal denervation procedure. The study was approved by each insti-
tution’s Research Ethics Committee and is registered with Clinical Trials
Registry (Registration No. NCT01438229). The trial is sponsored by St
Jude Medical, St Paul, Minnesota, USA.
Study procedure
Baseline
Following written informed consent, medical history, and physical exam-
ination including office BP were completed. The office BP was collected
according to the Standard Joint National Committee VII Guidelines and
ESC/ESH Guidelines.19,20 Each centre and each enrolled patient were
provided with an Automatic BP Monitor (Omron Healthcare, Inc., Ban-
nockburn, IL, USA) for collection of office and home BP values. All the
patients recorded home BP values (three readings in the morning and
three readings in the evening) and anti-hypertensive medication
regimendaily for aminimumof 14 days and completed a 24-h ambulatory
BP assessment. The 24-h ambulatory BPwas obtained by using anAmbu-
latory Blood Pressure System (Spacelabs Healthcare, Inc., Issaquah,WA,
USA).
After the 14-day-screening period, all the patients returned to their re-
spective study centre to complete the baseline assessment. Blood and
urine were collected for complete blood count, basic metabolic
profile, serum creatinine, estimated glomerular filtration rate (eGFR),
cystatin C, and urine albumin to creatinine ratio. An office BP assessment
using the BP monitor, a 12-Lead ECG and a review of medication logs
were also performed. Patients who did not meet all the inclusion criteria
or met one of the exclusion criteria were excluded from the study
(screen failures) and did not undergo the denervation procedure. In
total, 62 patients were consented for participation. Of those, 16 patients
were screen failures (Figure 1). Patients were scheduled for the renal de-
nervationprocedurewithin the following30days. Patientswere admitted
to the hospital on the day of the procedure.
Renal denervation procedure
Patients were taken to the catheterization laboratory to undergo the
renal denervation procedure. After administering conscious sedation
as described and local anaesthesia, using fluoroscopic guidance, an 8
French guiding catheter sheath [e.g. Cordis Vista Brite Tip Guiding Cath-
eter (New Jersey,USA)with renal double curve 1or another appropriate
guiding catheter sheath] was inserted to engage each main renal artery
sequentially. Nitroglycerine was injected directly into the renal artery if
needed. I.v. heparin was administered as per an institutional protocol
(3000–7000 U) although ACT monitoring was not mandated in the
protocol. Images of the left and right main renal arteries were recorded
using non-ionic contrast and the diameter and length of each of the main
renal arteries measured. Patients with small (,4 mm in diameter or
,20 mm in length), multiple main, or highly tortuous renal arteries
were excluded and did not undergo renal denervation. These patients
were followed for safety events and asked to return for a follow-up
visit at 6 months. An appropriate basket size was subsequently chosen
(small basket 4.0–5.5 mm diameter/large basket 5.5–8.0 mm diameter)
and the renal denervation catheter was inserted such that the catheter’s
tip is proximal to the bifurcation of one of the main renal arteries. The
basketon the catheterwas thenopenedwith the impedanceof eachelec-
trode on the basket monitored.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Key eligibility criteria
Inclusion criteria
Patient has an office systolic blood pressure that remains
≥160 mmHg (≥150 mmHg for patient with type 2 diabetes)
despite the stable use of ≥3 anti-hypertensive medications
concurrently at maximally tolerated doses, of which one is a
diuretic or patient was on diuretic previously but documented to
bediuretic intolerant, for aminimumof 14daysprior to Enrolment
and with an expectation to maintain for a minimum of 180 days
Patient is ≥18 and ≤80 years old
Exclusion criteria
Patient has evidence of renal artery stenosis (defined as a stenotic
severity of .30%) in either renal artery
Patient has multiple main renal arteries in either kidney
Patient’s main renal arteries are ,4 mm in diameter or ,20 mm in
length
Patient has an eGFR of ,45 mL/min per 1.73 m using the MDRD
formula
Patient has type 1 diabetes
Patient has an identified secondary cause of hypertension
Patient is in chronic atrial fibrillation/atrial flutter
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EnligHTN renal denervation system
The St Jude Medical EnligHTN
TM
renal denervation system used in this
study consists of the following main components: the EnligHTN
TM
Ablation Catheter and EnligHTN
TM




Ablation Catheter (St Jude Medical, St Paul, MN,
USA) was designed with an expandable electrode basket with four
Platinum–Iridium (Pt–Ir) ablation electrodes. The electrodes deliver
low-level RF energy to the renal arterial wall. The distal segment of the
ablation catheter is deflectable to assist in proper basket positioning.
Figure 1 Study flowchart.
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The expandable feature of the basket and the deflectable distal catheter
section establish good apposition between the ablation electrodes and
the target ablation sites in the renal artery. Each electrode has a tempera-
ture sensor to monitor the temperature at the ablation site.
The EnligHTN
TM
RF Ablation Generator delivers RF energy to the
EnligHTN
TM
Renal Artery Ablation Catheter using a proprietary algo-
rithm. Each electrode on the ablation catheter has a corresponding
display channel on the generator. The generator channels facilitate
control and monitoring of the ablation process. It consists of four inde-
pendent channels, which simultaneously monitor the temperature of
each of the four ablation electrodes and adjusts the magnitude of the
RF output power within the programmed maximum magnitude (6 W
per electrode) to achieve and maintain the desired temperature (758C)
at each ablation site. The generator has built-in safety features, which
include a self-test at power-up and automatic RF power shut-off if the
measured tissue impedance is ,50 Ohm or exceeds 400 Ohm or the
temperature exceeds the setting by .58C for .3 s or exceeds 808C.
Renal artery ablation
There were two sizes of the EnligHTN
TM
Ablation Catheter available for
use in the study. The small size basket is designed for renal artery dia-
meters between 4 and 6 mm, and the large size basket is designed for
renal artery diameters between 5.5 and 8 mm. After renal artery engage-
ment and completion of a renal angiogram, the EnligHTN
TM
Ablation
Catheter was inserted into the renal artery with the tip of the catheter
positioned proximal to the bifurcation and the corresponding images
recorded. The basket on the EnligHTN
TM
Ablation Catheter was then
opened with the impedance of each electrode on the basket monitored.
Renal artery denervation was commenced and performed sequentially
by all four electrodes with the impedance, temperature, and RF energy
deliverymonitored. If further ablationswere desired, the basket was col-
lapsed and pulled back a sufficient distance (1 cm) to avoid lesion
overlap. The basket was rotated 458 and then expanded. Placement
was confirmed under fluoroscopy and the ablation procedure was
repeated. A minimum of four to maximum of eight ablation sites were
performed in each main renal artery, with each ablation lasting 90 s per
electrode. In general, eight ablations were attempted per renal artery
to achieve circumferential ablation. Only one patient received four abla-
tions per arterywith similar BP reductions as the entire cohort. Images of
the renal arterywere takenusingnon-ionic contrast andchecked for signs
of renal artery irregularities (i.e. vasospasm, stenosis, or dissection). The
renal artery ablation procedure was then repeated for the other renal
artery, and the catheter was withdrawn. Finally, the sheath was
removed and haemostasis achieved according to each centre’s standard
of care. Procedural data were recorded for each patient, including pro-
cedure duration and number of ablations delivered.
Post-procedure and pre-discharge
Upon completion of the renal denervation procedure, the patient was
moved to a recovery area, and vital signs were monitored continuously.
BP was measured every 15 min during the first 2 h post-procedure and
then in 4-h intervals until discharge. Patients were discharged from the
hospital on the following day if medically stable.
Follow-up
Patients underwent the following during the post-discharge visits: office
BP assessment, review of medications for changes, 12-lead ECG, blood
and urine collection, 24-h ambulatory BP assessment, home BPmonitor-
ing, and renal arteryevaluation. Patientswere scheduled for the follow-up
visits at 1-, 3-, and 6-month (primary objective) post-procedure and con-
tinue being followed per study protocol at 12-, 18-, and 24-month post-
procedure. Renal artery imaging by computed tomography (CT) and
duplex ultrasound was completed at the 6-month follow-up visit. Renal
artery evaluation during the 1-month and 3-month follow-up visits was
performed if clinically indicated.
Study objectives
Theprimaryefficacyobjectivewas reductionofofficeBP frombaseline to
6 months, which was measured according to guidelines18,19 at baseline,
pre-discharge, 1-, 3-, and 6-month post-procedure. Additional efficacy
data collection included changes in anti-hypertensive medication, home
BP monitoring, and 24-h ambulatory BP. The primary safety objective
was the rate of AEs. Other data collection included blood analysis [com-
plete blood count, basic metabolic profile, serum creatinine concentra-
tion, eGFR (using the modified diet in renal disease (MDRD) formula)
and serum cystatin C], urine analysis (albumin-to-creatinine ratio),
12-lead ECG, and renal artery evaluation (using duplex ultrasonography
and/or CT scan).
Study oversight
Various independent committees or labs provided study oversight for
this trial. An independent Clinical Event Committee (CEC) adjudicated
all AEs. In addition, an independent Duplex Ultrasound (VasCore,
Boston, MA, USA) and CT scan core lab (Cornell University,
New York, NY, USA) interpreted the study images. Monitoring and
data analysis of the study was performed by St Jude Medical. The corre-
sponding author and SteeringCommitteemembers had full access to the
study data.
Statistical analysis
The minimum enrolment target for this study was 30 patients. No statis-
tical calculation of the sample size was undertaken, as this study was a
first-in-human study to evaluate safety and efficacy. All continuous para-
meters were summarized using mean, standard deviation, and range.
Normality of data was verified with the use of box plots and the Kolmo-
gorov–Smirnov normality test. For normally distributed data, compari-
sons of primary and secondary outcomes between time points were
analysed using paired t-tests. Correlations between variables were per-
formed using Pearson’s correlation co-efficients. In cases where the
data were not normally distributed, the non-parametric Wilcoxon
signed-rank test was used to analyse the data. All categorical parameters
were summarized using frequencies and percentages. Statistical analyses
were performed using SAS 9.2 (by SAS Institute, Inc., Cary, NC, USA).
Statistical significance was achieved if a two-sided test obtained a
P-value , 0.05.
Results
The study enrolment was conducted from October 2011 to March
2012. A total of 62 patients were consented for enrolment. Sixteen
patientswere excluded due to exclusion criteria during the screening
process. One of the 16 patients was excluded from the study due to
multiple renal arteries found on the screening renal angiogram. The
procedurewas discontinued per protocol (i.e. renal ablationnot per-
formed), and thepatientwas followeduntil 6-monthpost-procedure.
Refer to Figure 1 for further details of the excluded patients.
In total, 46 patients completed baseline evaluation and underwent
the renal denervation procedure. Forty large baskets (71%) and
sixteen small baskets (29%) EnligHTN catheters were used in total.
Forty EnligHTN catheters of the same size were used for both the
right and left renal arteries in patients (26 large and 14 small), and
thus sixteen catheters of varying sizes were used in the remaining
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patients. More than one EnligHTN catheter of coursemay have been
used per case independent of size. Forty four of the 46 (96%) met all
the inclusion and no exclusion criteria. There was one patient who
did not meet the inclusion criterion for office systolic BP of
.160 mmHg, and a patient who did not have the baseline BP assess-
ment completed per protocol. However, because these patients
underwent the procedure, they are included in the analysis (the
treated cohort). Baseline demographic, clinical condition, and medi-
cation data for the 46 patients are shown in Table 2. The procedure
was generally performed with conscious sedation at the operators’
discretion. This was not mandated in the protocol. It included, but
was not limited to the combination of i.v. midazolam and fentanyl,
titrated as appropriate. Most patients experienced back pain during
the denervation procedure, which was generally well controlled
with sedation and analgesia. Characteristics of the pain response
were not captured in detail. The median procedure time (from initi-
ation to completion of RF energy delivery) was 34.0 min and the
mean (+SD) number of ablations delivered was 7.7 (+0.8) for
the right and 7.4 (+1.4) for the left renal arteries. One patient had
the renal denervation procedure performed on a single side only
due to difficulty engaging the other renal artery. The mean fluoro-
scopic time was 11.0 (+7.1) min, and the mean contrast volume
used was 139.5 (+93.2) mL.
Safety objective
All theAEswere collected in the study.ACECadjudicated the events
for seriousness and relatedness to the procedure and device. A com-
plete list of reported procedure and/or device-related serious and
non-serious AEs as adjudicated by the CEC is provided in Table 3.
No serious vascular AEs occurred during the procedure, including
no renal artery damage (i.e. no renal artery dissections, aneurysms, or
flow limiting renal artery vasospasms) or serious vascular access site
complications. Minor peri-procedural events which were attributed
to either the device or procedure were reported and include:
non-flow limiting vasospasms, vascular access site haematomas,
hypotension, vasovagal episodes, bradycardia, transient haematuria,
pain, and nausea (Table 3). Vasospasm was reported as an AE al-
though no specific threshold was established for reporting the
event.An independantCECreviewedall vasospasmsanddetermined
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Baseline characteristics
Variable at baseline n 5 46
Age at baseline (years) 59.9+10.2 (32, 79)
Gender (male) 67.3% (31)
Ethnic origin (non-white) 2.2% (1)
Body mass index (kg/m2) 32.4+5.2
Diabetes mellitus type II 32.6% (15)
Coronary artery disease 19.6% (9)
Hyperlipidaemia 58.7% (27)
Sleep apnoea 30.4% (14)
Number of anti-hypertensive classes 4.1+0.57
Drug classification (number of patients) —
ACE inhibitors/ARBs/DRI 100% (46)
Beta-blockers 73.9% (34)
Calcium channel blockers 91.3% (42)
Diuretics 97.8% (45)
Aldosterone antagonists 13.0% (6)
Vasodilator 13.0% (6)
Sympatholytic agentsa 50.0% (23)
Data presented as mean+ SD or % (n).
ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; DRI,
direct renin inhibitors.
aa, blockers, combined a- and b-blockers and centrally acting a2 agonists.
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Table 3 Device and/or procedure-related adverse events
Event Number of events Number of subjects (%) Time of onset (average number of days
from procedure)
Serious adverse events
Hypertensive renal disease progression 1 1 (2) 93
Hypotension 1 1 (2) 137
Progression of pre-existing renal artery stenosis 1 1 (2) 169
Non-serious adverse events
Vasospasm 12 7 (15) 0
Haematoma 8 8 (17) 1
Hypotension 3 3 (7) 21
Vasovagal response 3 2 (4) 0
Bradycardia 2 2 (4) 0
Transient haematuria/discoloured urine 2 2 (4) 2
Pain—due to ablation 1 1 (2) 0
Pain—back discomfort 1 1 (2) 0
Nausea/vomiting 1 1 (2) 0
Hypertensive renal disease progression 1 1 (2) 85
Progression of pre-existing renal artery stenosis 1 1 (2) 173
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nonewere flow limiting (.50% reduction in vessel lumen diameter).
All minor peri-procedural events were reported to have resolved
without further clinical sequelae.
Serious AEs that were deemed possibly related to the procedure
and/or device were reported in three (6.5%) patients over 6 months
of follow-up. Events include hypotension, progressionof pre-existing
renal artery stenosis, and a progression of hypertensive renal disease
with an increase in serum creatinine.
Renal artery evaluation was conducted on all patients by CT
imaging at6months.Nopatientsdevelopedanewhaemodynamically
significant renal artery stenosis. Two patients with pre-existing renal
artery stenosis at baseline experienced asymptomatic progression of
their renal artery stenosis at 6 months. One was adjudicated as
serious (.50% occlusion in artery diameter) and one was non-
serious. Neither patient has required clinical intervention at 6
months and their renal functionparameters (eGFR, serumcreatinine,
and cystatin C values) remain stable.
Renal functionwas evaluated by repeatedmeasurements of eGFR,
serum creatinine and cystatin C from baseline through 6 months of
follow-up. No patient experienced a reduction in eGFR .50%, a
two-fold increase in serum creatinine, or progressed to end-stage
renal disease. While the eGFR decreased (baseline mean of
87–82 mL/min/1.73 m2 at 6 months, P-value ¼ 0.004) and serum
creatinine increased (baseline mean of 78–83 mmol/L at 6 months,
P-value ¼ 0.004), the mean cystatin C decreased (baseline mean of
1.14–1.00 mg/L at 6 months, P-value ¼ 0.00013). To further evalu-
ate changes in renal function, a more meaningful assessment of
eGFR with a clinically relevant cut-off of ,60 mL/min/1.73 m2 was
also undertaken. At baseline, three patients had an eGFR level of
,60 mL/min/1.73 m2. One of these patient’s eGFR remained ,60,
while the other two improved to 60 or greater at 6 months. In con-
trast, two other patients with baseline eGFR values.60 (63 and 61)
decreased to ,60 at 6 months.
The urine albumin-to-creatinine ratio decreased significantly
throughout the course of the study, with absolute results at baseline
169.4 mg/g, 1month 142.9 mg/g, 3months 141.2 mg/g, and 6months
139.3 mg/g (P ¼ 0.007).
Efficacy objectives
Compared with baseline, office and ambulatory systolic BP of the
entire cohort significantly decreased at all-time points (P-value ,
0.0001). The average office BP (mmHg) at baseline was 176/96
(mmHg). The resulting average office BP (mmHg) reductions from
baseline at 1 month, 3 months, and 6 months were 228/210,
227/210, and 226/210 (Figure 2). Over the follow-up period, as
many as 80% of patients had a reduction in office systolic BP of at
least 10 mmHg or greater and up to 41% had an office BP of ,
140 mmHg (Figure 3). Baseline systolic BP (P-value , 0.0001) was a
strong predictor of response.
In addition, the in-office resting heart ratewas collected at baseline
(71 b.p.m.), 1 month (69 b.p.m.), 3 months (67 b.p.m.), and 6 months
(66 b.p.m.) and demonstrated a decrease over time (P ¼ 0.007 at 6
months). The baseline HRwas a predictor of change in office systolic
BP (r ¼ 20.31, P ¼ 0.039). In addition, the reduction in HRwas cor-
related with reduction in office systolic BP (r ¼ 0.33, P ¼ 0.025).
The average 24-h ambulatory BP at baseline was 150/83 (mmHg).
The average 24-h ambulatory BP (mmHg) reduction frombaseline to
1 month, 3 months, and 6 months was 10/25, 210/25, and
210/26, respectively (Figure 4). The change in average 24-h ambula-
tory BP correlated with both the change in office systolic BP
(r ¼ 0.56, P, 0.0001) and office diastolic BP (r ¼ 0.55, P, 0.0001).
These reductions in office and ambulatory BPs were achieved with
minimal modifications to the cohort’s anti-hypertensive medical
regimen during the follow-up period. Over the 6-month follow-up
period, six (13.0%) patients had a decrease in their anti-hypertensive
medications and four (8.7%) had an increase in anti-hypertensive
Figure 2 Mean office blood pressure reduction (P-value , 0.001).
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medication(s). For patients that did not have an increaseor decrease in
their anti-hypertensivemedication(s) the 6-month office BP reduction
was similar to the entire cohort at 225/210 mmHg, as well as mean
ambulatory blood pressure (ABPM) reductions of 210/25 mmHg.
Discussion
This is the first-in-human, multi-centre study to evaluate the safety
and efficacy of a multi-electrode RF ablation catheter for renal
artery sympathetic denervation in patients with drug-resistant
HTN. A significant reduction in office and ambulatory BP was
demonstrated at all follow-up time points through 6 months. No
serious peri-procedural vascular events occurred and renal function
remained within expected range for a hypertensive population fol-
lowing the procedure and up to 6-month post-renal denervation.
The EnligHTN I data set is themost complete of those published in
the area of renal denervationwith all patients remaining enrolled and
followed through 6months (no deaths, lost to follow-up, or exits for
any reason). Only one visit was missed resulting in a 99.3% overall
follow-up visit compliance rate. The overall reductions in office BP
seen in the current study are comparable with those reported in
two previous studies where single electrode RF catheters were
Figure 3 Graphic display of the office systolic BP results for each of the patients enrolled at baseline and 6 months.
Figure 4 Mean ambulatory blood pressure reduction (P-value , 0.001).
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used.15,16 Of interest, reductions in BP were recorded earlier in the
current study (228/10 by 1 month), whereas previous studies
found thatwhile BPwas reduced at 1month, a comparable reduction
was not seen until 6 months.16 Arguably, the more rapid response
seen in the current study may reflect more complete renal denerv-
ation acutely due to the use of a multi-electrode RF catheter
system compared with a single electrode system. This variance may
simply reflect the limited sample sizes being addressed. The reduc-
tion in office systolic BP was greater than the reduction in 24 h
ABPM and is similar to the difference in the two measures as seen
in other studies. 15,16 One may argue this biases the endpoint
howeveroffice systolic BP is the gold standard for thediagnosis, treat-
ment, andmonitoring of patientswithHTN, therefore, the reduction
in office systolic BP is clinically meaningful.
We found a reduction in HR over 6 months, which is consistent
with previously published data,16,21 and consistent with a reduction
in sympathetic activity.We also identified baseline HR as a predictor
of reduction in office systolic BP, and change inHRover 6monthswas
correlated with office systolic BP reduction. Although this seems in-
tuitive and consistent with the hypothesis that the reduction in sym-
pathetic activity also drives the reduction in systolic BP, this is
different to a previous study.21 Some reasons for this difference
include the way heart rate was measured (in office HR assessment
from the BPmonitor vs. electrocardiogram), and the degree of base-
line sympathetic activity as evidenced by the baseline HR (71 vs. 66
b.p.m.). Clearly, larger observational data sets will assist in clarifying
such relationships.
The laboratory measures indicative of renal function vary slightly
over time; however, there is no abrupt change in eGFRor serum cre-
atinine immediately following the procedure. In addition, the cystatin
Cvalues improvedover time, as did theurinaryalbumin-to-creatinine
ratios, which suggest an improvement in renal function using these
indices. Although changes in eGFR and serum creatinine reach statis-
tical significance at 6 months, a shift of,6% is not considered clinic-
ally relevant, particularly in a population with normal renal function.
These changes can be attributed to a numberof reasons such as small
sample size, excessive diuretic dosage including aldosterone antago-
nists, natural variability andprogressionover time, or contrast admin-
istration for the 6-month protocol specified CT angiogram. The
protocol required a vascular image with contrast at 6 months, but
it did not specify the timing in relation to renal function evaluation.
It is possible that blood samples were collected after contrast admin-
istrationwhenusually a small transient rise in serumcreatininemaybe
noted. Nevertheless, renal function will be followed at 12 and 24
months and further assessment will be made. It is important to
note that the total number of patients with an eGFR,60was no dif-
ferent at baseline and 6 months (n ¼ 3).
Additional studies with larger sample sizes and a randomized con-
current control group would be beneficial in further assessing bene-
fits and risks of renal denervation therapy. A randomized trial
comparing outcomes between single electrode and multi-electrode
RF systems for renal denervation would allowmore direct compari-
son of potential advantages/disadvantages of the two systems, in par-
ticular whether earlier reduction in BP is achieved with the use of a
multi-electrode RF catheter. Current guidelines around clinical ap-
propriateness and future directions with regard renal denervation
have been very recently published.22
In conclusion, renal artery sympathetic denervation was per-
formed safely in patients with drug-resistant HTN, using the
EnligHTN
TM
multi-electrode catheter, and resulted in a rapid and sig-
nificant reduction in office BP as well as ambulatory BP that was sus-
tained through 6 months. Thus, the EnligHTN
TM
multi-electrode
system delivers a promising therapy for the treatment of
drug-resistant HTN.
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Do the findings on this ECG and echocardiogram
of this sportive patient with tightness of the chest
fit an athlete’s heart or do they indicate cardiac
pathology?
What are the criteria distinguishing physio-
logical—from pathological ventricular hypertrophy?
In an interactive educational case report com-
piled for theEuropeanSocietyofCardiology’s case-
based learning programme, the reader is shown a typical scenario in which diagnostic decisions need to be taken.
Explore the full case on the ESC’s case-based learning website at www.escardio.org/education/eLearning/case-based
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